Colombia | BCH-NR5-CO-284327 | Fifth National Report on the Implementation of the Cartagena Protocol on Biosafety

Article 2 – General provisions

Article 2 requires each Party to take the necessary and appropriate legal, administrative and other measures to implement its obligations under the Protocol

7. Has your country introduced the necessary national measures for the implementation of the Protocol?

National measures are partially in place

EN

8. Which specific instruments are in place for the implementation of national biosafety measures? (select all that apply)

One or more national biosafety laws
One or more national biosafety regulations
One or more sets of biosafety guidelines
Other laws, regulations or guidelines that indirectly apply to biosafety

Please provide further information on the instruments in place:

Se hace referencia a los siguientes leyes y reglamentaciones nacionales: Ley 740 de 2002: Por medio de la cual se aprueba el “Protocolo de Cartagena sobre Seguridad de la Biotecnología del Convenio sobre la Diversidad Biológica” Decreto 4525 de 2005: Por el cual se reglamenta la Ley 740 de 2002 Resolución 72221 de 2020: Por medio de la cual se implementa el plan de bioseguridad y seguimiento para siembras comerciales de cultivos genéticamente modificados con resistencia a plagas objetivo de la tecnología y/o tolerancia a la aplicación de herbicidas Resolución 91505 de 2021: Por medio de la cual se establece el trámite de las solicitudes de los Organismos Vivos Modificados-OVM con fines exclusivamente agrícolas, pecuarios, pesqueros, plantaciones forestales comerciales y agroindustriales ante el ICA Resolución 15141 de 2024: Por la cual se establecen los requisitos y condiciones para la producción, importación, exportación y almacenamiento de semillas producto del mejoramiento genético para la investigación, comercialización y siembra en el país, así como el registro de las Unidades de Evaluación Agronómica y/o Unidades de Investigación en Fitomejoramiento y se dictan otras disposiciones. Resolución 957 de 2010: “por la cual se establece el procedimiento para la autorización de actividades con Organismos Vivos Modificados –OVM– con fines exclusivamente ambientales, y se adoptan otras determinaciones” Resolución 958 de 2010: “por la cual se regula el funcionamiento del Comité Técnico Nacional de Bioseguridad para Organismos Vivos Modificados –OVM con fines exclusivamente ambientales que puedan tener efectos sobre el medio ambiente y la biodiversidad”. Decreto 4525 de 2005: Es el marco general que regula la bioseguridad de los OVM. Este decreto crea y organiza los Comités Técnicos Nacionales de Bioseguridad (CTN Bio), los cuales evalúan los riesgos de estos organismos antes de su introducción al país Resolución 4254 de 2011: la cual complementa las normas generales de rotulado como la Resolución 5109 de 2005

ES

9. Has your country integrated biosafety in national sectoral and cross-sectoral strategies, action plans, programmes, policies or legislation?

Yes

EN

10. Does your country have resources for biosafety from national budgets?

Yes

EN

Are these resources adequate:

No

EN

11. Does your country have qualified staff to administer functions directly related to biosafety?

Yes

EN

12. If you answered Yes to question 11, how many qualified staff members are in place whose functions are directly related to biosafety?

10 or more

EN

Is this number adequate:

No

EN

13. Please use the space below to provide further details on the implementation of Article 2 in your country:

Adicional a la normatividad interna relacionada `pregunta 8 existen una serie de directrices emitidas `por cada una de las autoridades nacionales competentes y que responden a necesidades específicas de la implementación del Protocolo de Cartagena tales como: Evaluación de riesgo, concienciación del público, fortalecimiento de capacidades, manipulación, transporte, envasado e identificación.

ES

Article 5 – Pharmaceuticals

14. Does your country regulate the transboundary movement, handling or use of living modified organisms (LMOs) which are pharmaceuticals for humans?

No

EN

15. Please use the space below to provide further details on the implementation of Article 5 in your country:

En Colombia no se regulan los OVMs que son productos farmacéuticos para seres humanos de acuerdo con el Artículo 5 del Protocolo de Cartagena

ES

Article 6 – Transit and contained use

16. Does your country regulate the transit of LMOs?

No

EN

17. Does your country regulate the contained use of LMOs?

Yes

EN

18. Has your country taken a decision concerning the import of LMOs for contained use?

Yes

EN

19. Please use the space below to provide further details on the implementation of Article 6 in your country:

Para el caso de OVM confinados de uso agropecuario, alimentación humana o salud humana se debe surtir un trámite que incluye una consulta pública, evaluación de riesgos y una decisión a través de un acto administrativo por parte de la Autoridad Nacional Competente; es importante recordar que hasta el momento no se han recibido solicitudes de OVM de uso exclusivamente ambiental

ES

Articles 7 to 10: Advance informed agreement (AIA) and intentional introduction of LMOs into the environment

20. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure?

No

EN

21. Has your country established legal requirements for the accuracy of information contained in the notification provided by exporters under its jurisdiction?

No

EN

22. In the current reporting period, has your country received a notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment?

Yes

EN

23. If you answered Yes to question 22, did the notification(s) contain complete information (at a minimum the information specified in Annex I to the Cartagena Protocol on Biosafety)?

Yes, always

EN

24. If you answered Yes to question 22, has your country acknowledged receipt of the notification(s) to the notifier within ninety days of receipt?

Yes, always

EN

25. If you answered Yes to question 22, has your country informed the following of its decision(s):

a. The notifier?

Yes, always

EN

b. The Biosafety Clearing-House (BCH)?

Yes, always

EN

26. In the current reporting period, has your country taken a decision in response to the notification(s) regarding intentional transboundary movements of LMOs for intentional introduction into the environment?

Yes

EN

Please specify how many

14

EN

27. If you answered Yes to question 26, what percentage of your country’s decisions fall into the following categories?

Approval of the import/use of the LMO(s) with conditions (93)
Prohibition of the import/use of the LMO(s) (7)

Were the reasons for the conditions provided?

Yes, always

EN

Were the reasons for the prohibition provided?

Yes

EN

28. If you answered Yes to question 26, how many LMOs has your country approved for import for intentional introduction into the environment?

10 or more

EN

29. If you answered under question 28 that LMOs were approved, have these LMOs actually been imported into your country?

Yes, always

EN

30. Please use the space below to provide further details on the implementation of Articles 7 to 10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment:

Para el caso de la introducción deliberada en el medio ambiente (siembras) se debe cumplir con las medidas de bioseguridad establecidas en la Resolución ICA 72221 de 2020; es importante recordar que hasta el momento no se han recibido solicitudes de OVM de uso exclusivamente ambiental

ES

Article 11 – Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)

31. Does your country have law(s), regulation(s) or administrative measures for decision-making regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?

Yes

EN

32. Has your country established legal requirements for the accuracy of information to be provided by the applicant regarding the domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?

Yes

EN

33. In the current reporting period, how many decisions has your country taken regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?

5 to 9

EN

34. Does your country have law(s), regulation(s) or administrative measures for decision-making regarding the import of LMOs for direct use as food or feed, or for processing?

Yes

EN

35. In the current reporting period, how many decisions has your country taken regarding the import of LMOs for direct use as food or feed, or for processing?

10 or more

EN

36. Please use the space below to provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing:

Las respuestas a las preguntas de 31 a la 33 se basan en el entendido para Colombia de que “uso nacional” se refiere a OVM-AHAP “desarrollados en el país” tal como se hace referencia en la pregunta 63 de los artículos 15 y 16. Se sugiere precisar en las preguntas de la 31 a la 33 si “uso nacional” incluye o no importaciones de OVM-AHAP y revisarlo a la luz del registro de un nuevo récord nacional sobre el uso de OVM-AHAP en el CIISB

ES

Article 12 – Review of decisions

37. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?

Yes

EN

38. In the current reporting period, has your country reviewed and/or changed a decision regarding an intentional transboundary movement of an LMO?

No

EN

39. If you answered Yes to question 38, how many decisions were reviewed and/or changed?

40. If you answered Yes to question 38, were any of the reviews triggered by a request from the Party of export or the notifier?

41. If you answered Yes to question 40, did your country provide a response within ninety days setting out the reasons for the decision?

42. If you answered Yes to question 38, were any of the reviews initiated by your country as the Party of import?

43. If you answered Yes to question 42, did your country, within thirty days, set out the reasons for the decision and inform:

a. The notifier?

b. The BCH?

44. Please use the space below to provide further details on the implementation of Article 12 in your country:

Para el caso de las autorizaciones de OVM de uso agropecuario se cuenta con los informes de línea base de susceptibilidad de las proteínas, plan de bioseguridad (Resolución ICA 72221 de 2020), actualización de los análisis bioinformáticos (Resolución 91505 de 2021). Para las autorizaciones de OVM de consumo humano se cuenta con los estudios de riesgos y estudios bioinformáticos, como soporte para las autorizaciones

ES

Article 13 – Simplified procedure

45. Has your country established a mechanism for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?

No

EN

46. In the current reporting period, has your country applied the simplified procedure?

No

EN

47. If you answered Yes to question 46, for how many LMOs has your country applied the simplified procedure?

48. If you answered Yes to question 46, has your country informed the Parties through the BCH of the cases where the simplified procedure was applied?

49. Please use the space below to provide further details on the implementation of Article 13 in your country:

EN

Article 14 – Bilateral, regional and multilateral agreements and arrangements

50. How many bilateral, regional or multilateral agreements or arrangements relevant to biosafety has your country established with other Parties/non-Parties?

1 to 4

EN

51. If you answered under question 50 that agreements or arrangements were established, please provide a brief description of their scope and objective:

Incluimos en la respuesta el Acuerdo sobre los términos de la adhesión de la República de Colombia a la Convención de la Organización para la Cooperación y el Desarrollo Económico, el TLC con Estados Unidos y decisiones relevantes de la Comunidad Andina

ES

52. Please use the space below to provide further details on the implementation of Article 14 in your country:

Colombia no ha celebrado acuerdos o arreglos bilaterales, regionales, multilaterales específicos para OVMs. Los referidos en la respuesta 51 abordan indirectamente ciertos aspectos de OVMs

ES

Articles 15 & 16 – Risk assessment and risk management

53. Does the domestic regulatory framework of your country require risk assessments of LMOs to be conducted?

Yes

EN

To which LMOs does this requirement apply (select all that apply):

For imports of LMOs for intentional introduction into the environment
For imports of LMOs intended for direct use as food or feed, or for processing
For decisions regarding domestic use, including placing on the market, of LMOs that may be subject to transboundary movements for direct use as food or feed, or for processing
For imports of LMOs for contained use

54. Has your country established a mechanism to conduct risk assessments prior to taking decisions regarding LMOs?

Yes

EN

Conducting risk assessment or risk management

55. In the current reporting period, has your country conducted any kind of risk assessment of LMOs, including for contained use, field trials, commercial purposes, direct use as food, feed, or for processing?

Yes

EN

56. If you answered Yes to question 55, how many risk assessments were conducted?

100 or more

EN

57. If you answered Yes to question 55, please indicate the scope of the risk assessments (select all that apply):

LMOs for contained use (in accordance with Article 3)
LMOs for intentional introduction into the environment for experimental testing or field trials
LMOs for intentional introduction into the environment for commercial purposes
LMOs for direct use as food
LMOs for direct use as feed
LMOs for processing

58. If you answered Yes to question 55, were risk assessments conducted for all decisions taken on LMOs for intentional introduction into the environment or on domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing?

Yes, always

EN

59. If you answered Yes to question 55, have you considered:

a. other available scientific evidence, as referred to in Article 15 of the Protocol?

No

EN

b. relevant traditional knowledge of indigenous peoples and local communities?

No

EN

60. If you answered Yes or In some cases to question 59(b), was this information considered in a scientifically sound manner?

61. Has your country established appropriate mechanisms, measures and strategies to regulate and manage risks identified in the risk assessment of LMOs?

Yes

EN

62. Has your country taken appropriate measures to prevent unintentional transboundary movements of LMOs including such measures as requiring a risk assessment to be carried out prior to the first release of a LMO? ¹

Yes

EN

63. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?

Yes

EN

64. Has your country established a mechanism for monitoring potential effects of LMOs released into the environment?

Yes

EN

65. Does your country have measures to identify LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?

Yes

EN

66. Has your country had access to or used any resource materials, including guidance documents, for the purpose of conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?

a. Risk assessment:

Yes

EN

b. Risk management:

Yes

EN

67. If you answered Yes to question 66(a) or (b), is your country using the “Guidance on Risk Assessment of LMOs” (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) ² for conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?

No

EN

68. Does your country have specific needs for further guidance on specific topics of risk assessment of LMOs?

Yes

EN

Additional Information

Guías de OVM de uso exclusivo ambiental, por ejemplo enfocado a microorganismos OVM; Guia para el uso adecuado de recursos bioinformáticos dentro de la evaluación de riesgos y para el manejo de proteínas a partir de eventos apilados

ES

Capacity-building in risk assessment or risk management

69. Does your country have the capacity to detect, identify, assess the risk of and/or monitor LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health?

a. Detect:

Yes

EN

b. Identify:

Yes

EN

c. Assess the risk:

Yes

EN

d. Monitor:

Yes

EN

70. In the current reporting period, how many people in your country have been trained in risk assessment, risk management and monitoring of LMOs?

a. Risk assessment:

10 to 49

EN

Is this number adequate:

No

EN

b. Risk management:

1 to 9

EN

Is this number adequate:

No

EN

c. Monitoring:

10 to 49

EN

Is this number adequate:

No

EN

71. Is your country using training material and/or technical guidance for training in risk assessment and risk management of LMOs?

Yes

EN

Which materials/guidance are being used

Manual on risk assessment of LMOs developed by the CBD Secretariat ³
Other materials/guidance: (OCDE, FAO y evaluaciones del riesgo de otros países.)

72. Please use the space below to provide further details on the implementation of Articles 15 and 16 in your country:

La respuesta a la pregunta 53 se basa en el entendido para Colombia de que “uso nacional” se refiere a OVM-AHAP “desarrollados en el país” tal como se hace referencia en la pregunta 63 de los artículos 15 y 16. La respuesta a la pregunta 66 no se limita al material desarrollado en el marco del protocolo, sino que se amplía a otras fuentes de referencia como por ejemplo, OCDE, FAO y evaluaciones del riesgo de otros países. Con respecto a la pregunta 67 la Guía se utiliza como uno de los materiales de referencia. Respecto a la pregunta 70 a. Se sugiere especificar si se hace referencia a actividades directamente organizadas por la Secretaría del Convenio o si tiene un sentido más amplio. Sobre la pregunta 70 b. Se aclara que fueron de 1 a 9 personas, adicionales a los más de 100 capacitados en el periodo comprendido en el Cuarto Informe

ES

Article 17 – Unintentional transboundary movements⁵ and emergency measures

⁵ In accordance with the operational definition adopted in decision CP-VIII/16, “‘Unintentional transboundary movement’ is a transboundary movement of a living modified organism that has inadvertently crossed the national borders of a Party where the living modified organism was released, and the requirements of Article 17 of the Protocol apply to such transboundary movements only if the living modified organism involved is likely to have significant adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health, in the affected or potentially affected States.”

73. Has your country established measures to notify affected or potentially affected States, the Biosafety Clearing-House and, where appropriate, relevant international organizations in case of a release under its jurisdiction that leads, or may lead, to an unintentional transboundary movement?

Yes, to some extent:

EN

Additional Information

Designación de Punto de Contacto de emergencia y en el Plan de Manejo de Bioseguridad, plan de Vigilancia y Control del ICA y del INVIMA

ES

74. In the current reporting period, how many releases of LMOs occurred under your country’s jurisdiction that led, or may have led, to an unintentional transboundary movement?

None

EN

75. If you answered under question 74 that a release occurred, has your country notified affected or potentially affected States, the Biosafety Clearing-House and, where appropriate, relevant international organizations?

76. In the current reporting period, how many times has your country become aware of an unintentional transboundary movement into its territory?

None

EN

77. Does your country have the capacity to take appropriate measures in response to unintentional transboundary movements?

Yes

EN

78. Please use the space below to provide further details on the implementation of Article 17 in your country:

Si bien se cuentan con ciertas capacidades para tomar medidas de respuesta es necesario robustecerlas. Se discutió la importancia de determinar si “liberación” en el contexto de la definición de “no intencional” se limita a liberación al ambiente o a cualquier tipo de decisión sobre el uso de un OVM

ES

Article 18 – Handling, transport, packaging and identification

79. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?

Yes, to some extent:

EN

Additional Information

Se cuenta con medidas amplias que incluyen los OVM-AHAP; con referencia a OVMs para la liberación al ambiente o estudios de campo, el país exige al notificador que informe los protocolos para cumplir esas medidas

ES

80. Has your country taken measures to require that documentation accompanying LMOs-FFP, in cases where the identity of the LMOs is not known, clearly identifies that they may contain LMOs and are not intended for intentional introduction into the environment, as well as a contact point for further information?

Yes

EN

81. Has your country taken measures to require that documentation accompanying LMOs-FFP, in cases where the identity of the LMOs is known, clearly identifies that they contain LMOs and are not intended for intentional introduction into the environment, as well as a contact point for further information?

Yes

EN

82. If you answered Yes or Yes, to some extent to question(s) 79, 80 and/or 81, what type of documentation accompanying LMOs does your country require?

Documentation specific to LMOs

EN

83. Has your country taken measures to require that documentation accompanying LMOs that are destined for contained use clearly identifies them as LMOs, and specifies any requirements for the safe handling, storage, transport and use, as well as the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?

Yes

EN

84. If you answered Yes or Yes, to some extent to question 83, what type of documentation does your country require for the identification of LMOs that are destined for contained use?

Documentation specific to LMOs

EN

85. Has your country taken measures to require that documentation accompanying LMOs that are intended for intentional introduction into the environment of the Party of import clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of the Cartagena Protocol applicable to the exporter?

Yes

EN

86. If you answered Yes or Yes, to some extent to question 85, what type of documentation does your country require for the identification of LMOs that are intended for intentional introduction into the environment?

Documentation specific to LMOs

EN

87. Does your country have the capacity to enforce the requirements of identification and documentation of LMOs?

Yes

EN

88. In the current reporting period, how many customs officers in your country have received training in the identification of LMOs?

10 to 49

EN

Is this number adequate:

No

EN

89. Has your country established procedures for the sampling and detection of LMOs?

Yes, to some extent:

EN

Additional Information

En cuanto a la pregunta 89, aún cuando las autoridades del sector agropecuario y salud humana poseen procedimientos para muestreo y detección de OVM, desde la ANC para ambiente se está trabajando en la construcción de estos lineamientos y capacidades operativa para su implementación

ES

90. Does your country have access to and use resource materials and detection methods to detect and identify LMOs?

a. access to resource materials and detection methods to detect and identify LMOs?

Yes

EN

b. use of resource materials and detection methods to detect and identify LMOs?

Yes

EN

91. Does your country have access to and use tools to detect and identify LMOs?

a. access to tools?

Yes

EN

b. use of tools?

Yes

EN

92. Does your country have access to and use certified reference materials necessary to detect and identify LMOs?

a. access to certified reference materials?

Yes

EN

b. use of certified reference materials?

Yes

EN

93. How many laboratory personnel in your country have received training in detection of LMOs?

1 to 9

EN

Is this number adequate:

No

EN

94. Does your country have reliable access to technical infrastructures, such as laboratories for the detection and identification of LMOs?

a. technical infrastructure for detection of LMOs?

Yes

EN

b. technical infrastructure for identification of LMOs

Yes

EN

95. How many laboratories in your country are certified for LMO detection?

1 to 4

EN

96. If you answered under question 95 that certified laboratories exist in your country, how many of them are currently operating in the field of the detection of LMOs?

1 to 4

EN

97. Please use the space below to provide further details on the implementation of Article 18 in your country:

Para la pregunta 80 se responde en el entendido de que se trata de OVMs para uso en investigación, en los que todavía no se ha otorgado un identificador único

ES

Article 19 – Competent national authorities and national focal points

98. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs?

Yes

EN

99. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety?

Yes, to some extent:

EN

Additional Information

Aunque se cuenta con capacidades institucionales, es necesario fortalecer las capacidades relacionadas con cantidad y entrenamiento de personal, presupuesto, infraestructura, entre otros

ES

100. Has your country undertaken initiatives to strengthen collaboration among national focal points, competent national authority(ies) and other institutions on biosafety-related matters?

Yes

EN

Additional Information

Existen acciones de colaboración y trabajo conjunto, siendo necesario fortalecer aspectos como el involucramiento de actores no gubernamentales

ES

101. Please use the space below to provide further details on the implementation of Article 19 in your country:

EN

Article 20 – Information-sharing and the Biosafety Clearing-House (BCH):

102. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available ⁶ and whether it has been submitted to the BCH:

a. Existing legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3(a))

Information available and in the BCH

EN

b. Legislation, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)

Information available and in the BCH

EN

c. Bilateral, multilateral and regional agreements and arrangements (Article 14, paragraph 2, and Article 20, paragraph 3 (b))

Information not available

EN

d. Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3(e))

Information available and in the BCH

EN

e. Decisions regarding transit of LMOs (Article 6, paragraph 1)

Information not available

EN

f. Decisions regarding import of LMOs for contained use (Article 6, paragraph 2)

Information available and in the BCH

EN

g. Notifications regarding the release under your country’s jurisdiction that leads, or may lead, to an unintentional transboundary movement of a LMO that is likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)

Information not available

EN

h. Information concerning cases of illegal transboundary movements of LMOs (Article 25, paragraph 3)

Information not available

EN

i. Decisions regarding the importation of LMOs for intentional introduction into the environment (Article 10, paragraph 3)

Information available and in the BCH

EN

j. Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)

Information available and in the BCH

EN

k. Decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)

Information not available

EN

l. Decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with Annex III to the Protocol (Article 11, paragraph 6)

Information available and in the BCH

EN

m. Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)

Information not available

EN

n. Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)

Information not available

EN

o. Cases where intentional transboundary movement may take place at the same time as the movement is notified to your country (Article 13, paragraph 1(a))

Information not available

EN

p. LMOs exempted from the advance informed agreement procedure (Article 13, paragraph 1(b))

Information not available

EN

q. Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3(c))

Information not available

EN

103. Please provide a brief explanation if you answered that the information is available but not in the BCH or only partially available in the BCH to any item under question 102:

EN

104. Has your country established a mechanism for the coordination among the BCH national focal point, the Cartagena Protocol national focal point, and the competent national authority(ies) for making information available to the BCH?

Yes

EN

105. In the current reporting period, has your country used the information available in the BCH in its decision-making processes on LMOs?

Yes, always

EN

106. In the current reporting period, has your country experienced difficulties accessing or using the BCH?

No

EN

107. Does your country have a national biosafety clearing-house?

No

EN

108. Please use the space below to provide further details on the implementation of Article 20 in your country:

102 c. Colombia responde información no disponible en virtud a que no se han suscrito acuerdos o arreglos bilaterales, regionales y multilaterales en la materia (artículo 14, párrafo 2, y artículo 20, párrafo 3 b). 102 e. Colombia responde información no disponible en razón a que no se han dado decisiones sobre tránsito de OVMs en el territorio nacional 102 g. Colombia responde información no disponible en razón a que no se han dado movimientos transfronterizos involuntarios de OVMs en el territorio nacional. 102 k. Colombia responde información no disponible en razón a que no se han dado las situaciones en cuestión. Colombia está en proceso de desarrollos nacionales, en investigación, pero no hay decisiones finales. 102 m. Colombia cuenta con un marco normativo específico correspondiente, no ha sido necesario tomar decisiones en ausencia de un marco normativo nacional. 102 n. Colombia responde información no disponible en razón a que no se han presentado las situaciones en cuestión. Colombia no ha realizado revisiones o modificaciones de decisiones. 102 o. Colombia no tiene establecido un procedimiento simplificado (artículo 13, párrafo 1 a). 102 p. Colombia no tiene establecido un procedimiento simplificado (artículo 13, párrafo 1 b). 102 q. Colombia no ha realizado evaluaciones de riesgo o exámenes sobre productos derivados de OVMs. De forma general para la pregunta 102 se sugiere incluir casilla de opción para cuando el ítem no aplica ‘N/A’ (Ej. Información no disponible en razón que la situación en cuestión no se ha presentado).

ES

Article 21 – Confidential information

109. Has your country established procedures to protect confidential information received under the Protocol?

Yes

EN

110. Does your country allow the notifier to identify information that is to be treated as confidential?

Yes, always

EN

111. Please use the space below to provide further details on the implementation of Article 21 in your country:

EN

Article 22 – Capacity-building

112. Does your country have predictable and reliable funding for its capacity-building needs for the effective implementation of the Protocol?

No

EN

113. Has your country received external support for the development and/or strengthening of human resources and institutional capacities in biosafety?

No

EN

114. If you answered Yes or Yes, to some extent to question 113, how was this support made available?

115. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?

Yes

EN

Additional Information

Se brindó fortalecimiento de capacidades a entidades homólogas a través de la Red Latinoamericana y del Caribe de Laboratorios de detección de OGMs (RELAC OGM)]

ES

116. If you answered Yes to question 115, how was this support made available?

Regional channels

117. In the current reporting period, has your country used its GEF STAR allocation for biosafety activities?

No

EN

118. In the current reporting period, has your country undertaken activities for the development and/or strengthening of human resources and institutional capacities in biosafety?

Yes, to some extent:

EN

Additional Information

Se tiene actividades de capacitación y entrenamiento a profesionales técnicos y de campo, especialmente por parte del sector agropecuario y salud

ES

119. If you answered Yes or Yes, to some extent to question 118, in which of the following areas were these activities undertaken (select all that apply)?

Institutional capacity and human resources
Integration of biosafety in cross-sectoral and sectoral legislation, policies and institutions (mainstreaming biosafety)
Risk management
Public awareness, participation and education in biosafety
Information exchange and data management, including participation in the Biosafety Clearing-House
Scientific, technical and institutional collaboration at subregional, regional and international levels
Identification of LMOs, including their detection
Implementation of the documentation requirements under Article 18.2 of the Protocol
Measures to address unintentional and/or illegal transboundary movements of LMOs
Taking into account risks to human health

120. If you answered Yes or Yes, to some extent to question 118, did your country use capacity-building materials, including online resources, for the development and/or strengthening of capacity-building?

Yes

EN

121. In the current reporting period, has your country carried out a capacity-building needs assessment?

Yes

EN

122. Does your country still have capacity-building needs?

Yes

EN

123. If you answered Yes to question 122, which of the following areas still need capacity-building (select all that apply)?

Institutional capacity and human resources
Integration of biosafety in cross-sectoral and sectoral legislation, policies and institutions (mainstreaming biosafety)
Risk assessment and other scientific and technical expertise
Risk management
Public awareness, participation and education in biosafety
Information exchange and data management, including participation in the Biosafety Clearing-House
Scientific, technical and institutional collaboration at subregional, regional and international levels
Technology transfer
Sampling, detection and identification of LMOs
Socioeconomic considerations
Implementation of the documentation requirements for handling, transport, packaging and identification
Handling of confidential information
Measures to address unintentional and/or illegal transboundary movements of LMOs
Scientific biosafety research relating to LMOs
Taking into account risks to human health
Liability and redress

124. If you answered Yes to question 122, has your country prioritized its capacity-building needs?

No

EN

125. Does your country have in place a functional national mechanism for coordinating biosafety capacity-building initiatives?

No

EN

126. Please use the space below to provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds:

Se identifican oportunidades para avanzar en los procesos de fortalecimiento de capacidades en el país, para mejorar situaciones como: falta de continuidad del personal técnico, desarticulación intrainstitucional del sector ambiente, reducción de recursos financieros asignados para la vinculación del personal, alta rotación de personal con curvas de aprendizaje prolongadas debido a la tecnicidad y complejidad del tema. 121. Desde el sector ambiente se ha adelantado un diagnóstico y elaborado una estrategia de construcción y fortalecimiento de capacidades, que identifica líneas estratégicas para avanzar en la implementación del Protocolo de Cartagena

ES

Article 23 – Public awareness and participation

127. Is biosafety public awareness, education and/or participation addressed in legislation or policy in your country?

Yes

EN

128. Has your country established a mechanism to ensure public access to information on LMOs?

Yes

EN

Additional Information

A través de los sitios web de las autoridades nacionales competentes se encuentra disponible información sobre los OVMs y la seguridad de la biotecnología

ES

129. Has your country established a mechanism to facilitate and promote public participation, including consultation, in the decision-making process regarding LMOs?

Yes

EN

130. Has your country informed the public about existing modalities for public participation in the decision-making process regarding LMOs?

Yes

EN

131. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs?

5 or more

EN

132. In the current reporting period, has your country made the results of decisions regarding LMOs available to the public?

Yes

EN

133. Has your country informed the public about the means to access the Biosafety Clearing-House?

No

EN

134. Has biosafety been addressed or integrated in educational and training programmes in your country?

No

EN

135. Does your country have in place a national communication strategy on biosafety?

No

EN

136. Does your country have any awareness and outreach programmes on biosafety?

Yes

EN

Additional Information

Se han adelantado acciones o actividades sectoriales para la concienciación y divulgación de la seguridad de la biotecnología y OVMs. Existe un programa nacional acotado para el sector agropecuario

ES

137. Does your country currently have a national biosafety website?

No

EN

138. In the current reporting period, has your country accessed resource materials for facilitating and promoting public awareness, education and participation in biosafety?

Yes

EN

139. Please use the space below to provide further details on the implementation of Article 23 in your country:

133. Desde el sector agropecuario se han adelantado acciones de concienciación y divulgación sobre la forma el objeto, acceso y uso del CIISB, a diferentes actores involucrados o interesados en temas de seguridad de biotecnología y OVMs

ES

Article 24 – Non-Parties

140. Has your country entered into any bilateral, regional, or multilateral agreement(s) with non-Parties regarding transboundary movements of LMOs?

No

EN

141. In the current reporting period, has your country imported LMOs from a non-Party?

Yes

EN

142. In the current reporting period, has your country exported LMOs to a non-Party?

Yes

EN

143. If you answered Yes to question 141 and/or 142, were the transboundary movements of LMOs consistent with the objective of the Cartagena Protocol on Biosafety?

Yes, always

EN

144. Please use the space below to provide further details on the implementation of Article 24 in your country:

EN

Article 25 – Illegal transboundary movements ⁷

⁷ In accordance with the operational definition adopted in decision CP-VIII/16, “‘Illegal transboundary movement’ is a transboundary movement of living modified organisms carried out in contravention of the domestic measures to implement the Protocol that have been adopted by the Party concerned”

145. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement the Cartagena Protocol?

Yes

EN

146. In the current reporting period, how many cases of illegal transboundary movements of LMOs has your country become aware of?

None

EN

147. If you indicated under question 146 that your country became aware of cases of illegal transboundary movements, has the origin of the LMO(s) been established?

148. Please use the space below to provide further details on the implementation of Article 25 in your country:

EN

Article 26 – Socio-economic considerations

149. Does your country have any specific approaches or requirements that facilitate how socioeconomic considerations should be taken into account in LMO decision-making?

No

EN

150. Has your country used resource materials for taking socioeconomic considerations into account?

No

EN

151. In the current reporting period, have socioeconomic considerations arising from the impact of LMOs been taken into account in decision-making?

No

EN

152. Please use the space below to provide further details on the implementation of Article 26 in your country:

EN

Article 28 – Financial mechanism and resources

153. In the current reporting period, how much funding (in the equivalent of US dollars) has your country mobilized to support implementation of the Cartagena Protocol beyond the regular national budgetary allocation?

None

EN

Article 33 – Monitoring and reporting

Article 33 requires Parties to monitor the implementation of its obligations under the Cartagena Protocol and to report to the Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol on measures taken to implement the Protocol.

154. Does your country have in place a system to monitor and enforce the implementation of the Cartagena Protocol?

Yes

EN

Cooperation

Goal B.4 of the Implementation Plan for the Cartagena Protocol addresses cooperation and coordination on biosafety issues at the national, regional and international levels. Questions related to this goal are presented below, including questions related to cooperation under different provisions of the Protocol.

155. In the current period, has your country cooperated with other Parties in:

a. exchange of scientific, technical and institutional knowledge;

Yes

EN

b. identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity? (Article 16(5)).

No

EN

c. research and information exchange on any socioeconomics impacts of LMOs? (Article 26(2))

No

EN

Does this include research and information exchange on socioeconomic impacts of LMOs on indigenous peoples and local communities?

d. public awareness, education and participation? (Article 23(1)(a))

No

EN

e. strengthening capacities for the implementation of the Protocol?

Yes

EN

156. In the current reporting period, has your country engaged in bilateral, regional or multilateral activities for the implementation of the Protocol?

Yes

EN

157. Does your country have mechanisms in place for involving indigenous peoples and local communities and relevant stakeholders from different sectors in the implementation of the Protocol?

a. mechanisms for involving indigenous peoples and local communities

Yes

EN

b. mechanisms for involving relevant stakeholders from different sectors

Yes

EN

158. Please use the space below to provide further details on biosafety cooperation in your country:

EN

Nagoya – Kuala Lumpur Supplementary Protocol on Liability and Redress

Parties to the Cartagena Protocol that are not yet Party to the Supplementary Protocol are also invited to respond to the questions below

159. Is your country a Party to the Nagoya – Kuala Lumpur Supplementary Protocol on Liability and Redress?

Yes

EN

Is there any national process in place towards becoming a Party to the Supplementary Protocol?

160. Has your country introduced the necessary measures for the implementation of the Supplementary Protocol?

No measures have yet been taken

EN

161. Which instruments are in place for the implementation of the Supplementary Protocol (select all that apply)?

One or more national laws

Please provide further information on the instruments in place:

Ley 1926 de 2018 “por medio de la cual se aprueba el Protocolo de Nagoya - Kuala Lumpur sobre Responsabilidad y Compensación Suplementario al Protocolo de Cartagena sobre Seguridad de la Biotecnología

ES

162. Does your country have administrative or legal instruments that require response measures to be taken:

a. In case of damage resulting from LMOs?

No

EN

b. In case there is sufficient likelihood that damage will result if response measures are not taken?

No

EN

163. If you answered Yes to question 162a, do these instruments impose requirements on an operator (select all that apply)?

164. If you answered Yes to question 162a, do these instruments require the operator to take response measures to avoid damage?

165. If you answered Yes to question 162a or 162b, do these instruments provide for a definition of “operator”?

166. If you answered Yes to question 165, which of the following could be an ‘operator’ (select all that apply)?

167. Has a competent authority been identified for carrying out the functions set out in the Supplementary Protocol?

No

EN

168. If you answered Yes to question 167, what measures may the competent authority take (select all that apply)?

169. Does your country have measures in place to provide for financial security for damage resulting from LMOs?

No

EN

170. If you answered Yes to question 169, what type of financial security measures are in place (select all that apply)?

171. Does your country have rules and procedures on civil liability that address damage resulting from LMOs, or has such damage been recognized in court rulings (select all that apply)?

No

172. Have there been any occurrences of damage resulting from LMOs in your country?

No

EN

173. If you answered Yes to question 172, have response measures been taken?

174. Please use the space below to provide further details on any activities undertaken in your country towards the implementation of the Nagoya – Kuala Lumpur Supplementary Protocol on Liability and Redress:

Respecto a la pregunta 171, en el ámbito jurisprudencial interno, se identifica como relevante la Sentencia T-247 de 2023, mediante la cual la Corte Constitucional ordenó a diferentes entidades relacionadas con la implementación en Colombia del Protocolo de Cartagena, adelantar, en aplicación del Principio de Precaución, entre otras medidas estudios o evaluaciones técnicas que permitan analizar los efectos al medio ambiente o a la salud derivados del uso de organismos vivos modificados, en relación con semillas nativas y criollas de maíz en territorios de los Pueblos Indígenas accionantes de la Sentencia. No obstante, dicha providencia no declaró la causación de un daño en los términos definidos por el Protocolo Suplementario Nagoya-Kuala Lumpur (Artículo 2), ni estableció responsabilidad civil derivada de OVM. Su relevancia radica, principalmente, en el fortalecimiento del enfoque preventivo y precautorio en la gestión del riesgo, así como en la exigencia de soporte técnico para valorar la suficiencia de las medidas regulatorias vigentes.

ES

Other information

175. Please use this field to provide any other information on issues related to national implementation of the Cartagena Protocol and the Supplementary Protocol, including any obstacles or impediments encountered:

EN

Comments on reporting format

176. Please use this field to provide any information on difficulties that you have encountered in filling in this report, and suggestions for its improvement:

En algunos casos no se encuentra una adecuada traducción del inglés al español.

Se sugiere mejorar la estandarización en el uso del lenguaje, en particular en el caso de los términos de desarrollo local y uso nacional.

Para preguntas con respuestas en rangos numéricos, los rangos predeterminados no siempre permiten reflejar con precisión la realidad

ES

This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.

This document has been updated. This is not the latest published version. Click here to view the latest version of the record.

Comparing version with latest version 1

Quick links

Need help?

THE CONVENTION ON BIOLOGICAL DIVERSITY

Quick Links

Topics

Information

A part of

This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.

This document has been updated. This is not the latest published version. Click here to view the latest version of the record.

Comparing version with latest version 1 Close comparison

Quick links

Need help?

THE CONVENTION ON BIOLOGICAL DIVERSITY

Quick Links

Topics

Information

A part of

Comparing version with latest version 1